Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in:

Open Access 01-12-2024 | Metabolic Dysfunction-Associated Steatotic Liver Disease | Review

Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review

Authors: Haixiang Zheng, Leonardo Antonio Sechi, Eliano Pio Navarese, Gavino Casu, Gianpaolo Vidili

Published in: Cardiovascular Diabetology | Issue 1/2024

Login to get access

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed nonalcoholic fatty liver disease (NAFLD), poses a significant global health challenge due to its increasing prevalence and strong association with cardiovascular disease (CVD). This comprehensive review summarizes the current knowledge on the MASLD-CVD relationship, compares analysis of how different terminologies for fatty liver disease affect cardiovascular (CV) risk assessment using different diagnostic criteria, explores the pathophysiological mechanisms connecting MASLD to CVD, the influence of MASLD on traditional CV risk factors, the role of noninvasive imaging techniques and biomarkers in the assessment of CV risk in patients with MASLD, and the implications for clinical management and prevention strategies. By incorporating current research and clinical guidelines, this review provides a comprehensive overview of the complex interplay between MASLD and cardiovascular health.
Literature
1.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.PubMedCrossRef
2.
Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73(4):691–702.PubMed
3.
Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–9.PubMedCrossRef
4.
Gofton C, Upendran Y, Zheng MH, George J. MAFLD: how is it different from NAFLD? Clin Mol Hepatol. 2023;29(Suppl):S17–31.PubMedCrossRef
5.
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542–56.PubMedCrossRef
6.
Diehl AM, Day C. Cause, Pathogenesis, and treatment of Nonalcoholic Steatohepatitis. N Engl J Med. 2017;377(21):2063–72.PubMedCrossRef
7.
Kaya E, Yilmaz Y. Metabolic-associated fatty liver Disease (MAFLD): a multi-systemic disease beyond the liver. J Clin Transl Hepatol. 2022;10(2):329–38.PubMedCrossRef
8.
Tsutsumi T, Nakano D, Hashida R, Sano T, Kawaguchi M, Amano K, Kawaguchi T. The Inter-organ Crosstalk reveals an inevitable link between MAFLD and Extrahepatic diseases. Nutrients 2023, 15(5).
9.
Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138–53.PubMedCrossRef
10.
Li AA, Ahmed A, Kim D. Extrahepatic manifestations of nonalcoholic fatty liver disease. Gut Liver. 2020;14(2):168–78.PubMedCrossRef
11.
Lee HH, Lee HA, Kim EJ, Kim HY, Kim HC, Ahn SH, Lee H, Kim SU. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Gut. 2024;73(3):533–40.PubMed
12.
Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65(3):589–600.PubMedCrossRef
13.
Janssen A, Grobbee DE, Dendale P. Non-alcoholic fatty liver disease, a new and growing risk indicator for cardiovascular disease. Eur J Prev Cardiol. 2020;27(10):1059–63.PubMedCrossRef
14.
Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. J Hepatol. 2016;65(2):425–43.PubMedCrossRef
15.
Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS. Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(8):948–63.PubMedCrossRef
16.
17.
Kasper P, Martin A, Lang S, Kutting F, Goeser T, Demir M, Steffen HM. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021;110(7):921–37.PubMedCrossRef
18.
Pan Z, Shiha G, Esmat G, Mendez-Sanchez N, Eslam M. MAFLD predicts cardiovascular disease risk better than MASLD. Liver Int 2024.
19.
Ciardullo S. The MAFLD-MASLD debate: does cardiovascular risk prediction define the winner? Liver Int. 2024;44(7):1564–6.PubMedCrossRef
20.
Ramirez-Mejia MM, Jimenez-Gutierrez C, Eslam M, George J, Mendez-Sanchez N. Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification? Hepatol Int. 2024;18(1):168–78.PubMedCrossRef
21.
Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the study of liver diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005–23.PubMedCrossRef
22.
Cheng YM, Wang CC, Kao JH. Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications. Hepatol Int. 2023;17(2):350–6.PubMedCrossRef
23.
Xu X, Zhou X, Tian T, Ding Y, Yu C, Zhao W, Wang X, Lu J, Guo W, Jiang L, et al. Comparison of clinical characteristics and outcomes of MAFLD and NAFLD in Chinese Health examination populations. J Clin Transl Hepatol. 2023;11(4):777–86.PubMedPubMedCentral
24.
Hagstrom H, Vessby J, Ekstedt M, Shang Y. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol. 2024;80(2):e76–7.PubMedCrossRef
25.
Kang MK, Song J, Loomba R, Park S, Tak W, Kweon Y, Lee Y, Park JG. Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification. 2024.
26.
Ciardullo S, Mantovani A, Morieri ML, Muraca E, Invernizzi P, Perseghin G. Impact of MASLD and MetALD on clinical outcomes: a meta-analysis of preliminary evidence. Liver Int. 2024;44(8):1762–7.PubMedCrossRef
27.
Choe HJ, Moon JH, Kim W, Koo BK, Cho NH. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: a community-dwelling cohort study with 20-year follow-up. Metabolism. 2024;153:155800.PubMedCrossRef
28.
Aedh AI, Alshahrani MS, Huneif MA, Pryme IF, Oruch R. A glimpse into milestones of insulin resistance and an updated review of its management. Nutrients 2023, 15(4).
29.
Pal SC, Mendez-Sanchez N. Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis. World J Gastroenterol. 2023;29(25):3999–4008.PubMedPubMedCentralCrossRef
30.
Zhao J, Wu Y, Rong X, Zheng C, Guo J. Anti-lipolysis Induced by insulin in diverse pathophysiologic conditions of adipose tissue. Diabetes Metab Syndr Obes. 2020;13:1575–85.PubMedPubMedCentralCrossRef
31.
Kosmas CE, Bousvarou MD, Kostara CE, Papakonstantinou EJ, Salamou E, Guzman E. Insulin resistance and cardiovascular disease. J Int Med Res. 2023;51(3):3000605231164548.PubMedCrossRef
32.
Yang K, Song M. New Insights into the pathogenesis of metabolic-associated fatty liver disease (MAFLD): gut-liver-heart crosstalk. Nutrients 2023, 15(18).
33.
Zhao J, Liu L, Cao YY, Gao X, Targher G, Byrne CD, Sun DQ, Zheng MH. MAFLD as part of systemic metabolic dysregulation. Hepatol Int 2024.
34.
Burger K, Jung F, Baumann A, Brandt A, Staltner R, Sanchez V, Bergheim I. TNFalpha is a key trigger of inflammation in diet-induced non-obese MASLD in mice. Redox Biol. 2023;66:102870.PubMedPubMedCentralCrossRef
35.
Zhu M, Lei L, Zhu Z, Li Q, Guo D, Xu J, Chen J, Sha H, Zhang X, Yang X, et al. Excess TNF-alpha in the blood activates monocytes with the potential to directly form cholesteryl ester-laden cells. Acta Biochim Biophys Sin (Shanghai). 2015;47(11):899–907.PubMedCrossRef
36.
Rafaqat S, Gluscevic S, Mercantepe F, Rafaqat S, Klisic A. Interleukins: pathogenesis in non-alcoholic fatty liver disease. Metabolites 2024, 14(3).
37.
Duan Y, Pan X, Luo J, Xiao X, Li J, Bestman PL, Luo M. Association of inflammatory cytokines with non-alcoholic fatty liver disease. Front Immunol. 2022;13:880298.PubMedPubMedCentralCrossRef
38.
Ngwa DN, Pathak A, Agrawal A. IL-6 regulates induction of C-reactive protein gene expression by activating STAT3 isoforms. Mol Immunol. 2022;146:50–6.PubMedPubMedCentralCrossRef
39.
Medina-Leyte DJ, Zepeda-Garcia O, Dominguez-Perez M, Gonzalez-Garrido A, Villarreal-Molina T, Jacobo-Albavera L. Endothelial dysfunction, inflammation and coronary artery disease: potential biomarkers and promising therapeutical approaches. Int J Mol Sci. 2021;22(8).
40.
Castillo-Nunez Y, Almeda-Valdes P, Gonzalez-Galvez G, Arechavaleta-Granell MDR. Metabolic dysfunction-associated steatotic liver disease and atherosclerosis. Curr Diab Rep. 2024;24(7):158–66.PubMedCrossRef
41.
Ma Y, Lee G, Heo SY, Roh YS. Oxidative stress is a key modulator in the development of nonalcoholic fatty liver disease. Antioxid (Basel) 2021, 11(1).
42.
Batty M, Bennett MR, Yu E. The role of oxidative stress in atherosclerosis. Cells 2022, 11(23).
43.
Munzel T, Camici GG, Maack C, Bonetti NR, Fuster V, Kovacic JC. Impact of oxidative stress on the heart and vasculature: part 2 of a 3-Part series. J Am Coll Cardiol. 2017;70(2):212–29.PubMedPubMedCentralCrossRef
44.
45.
Kruger-Genge A, Blocki A, Franke RP, Jung F. Vascular endothelial cell Biology: an update. Int J Mol Sci 2019, 20(18).
46.
Nasiri-Ansari N, Androutsakos T, Flessa CM, Kyrou I, Siasos G, Randeva HS, Kassi E, Papavassiliou AG. Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review. Cells 2022, 11(16).
47.
Andrabi SM, Sharma NS, Karan A, Shahriar SMS, Cordon B, Ma B, Xie J. Nitric oxide: physiological functions, delivery, and biomedical applications. Adv Sci (Weinh). 2023;10(30):e2303259.PubMedCrossRef
48.
49.
Gunawardena T, Merinopoulos I, Wickramarachchi U, Vassiliou V, Eccleshall S. Endothelial dysfunction and coronary vasoreactivity - A review of the history, physiology, diagnostic techniques, and clinical relevance. Curr Cardiol Rev. 2021;17(1):85–100.PubMedPubMedCentralCrossRef
50.
Shimabukuro M. MAFLD and small dense LDL cholesterol: a mechanistic link. J Atheroscler Thromb. 2024;31(1):17–8.PubMedCrossRef
51.
52.
Virovic-Jukic L, Stojsavljevic-Shapeski S, Forgac J, Kukla M, Mikolasevic I. Non-alcoholic fatty liver disease - a procoagulant condition? Croat Med J. 2021;62(1):25–33.PubMedPubMedCentralCrossRef
53.
Ogresta D, Mrzljak A, Cigrovski Berkovic M, Bilic-Curcic I, Stojsavljevic-Shapeski S, Virovic-Jukic L. Coagulation and endothelial dysfunction Associated with NAFLD: current status and therapeutic implications. J Clin Transl Hepatol. 2022;10(2):339–55.PubMedPubMedCentralCrossRef
54.
Gallo G, Savoia C. New insights into endothelial dysfunction in cardiometabolic diseases: potential mechanisms and clinical implications. Int J Mol Sci 2024, 25(5).
55.
Shabalala SC, Dludla PV, Mabasa L, Kappo AP, Basson AK, Pheiffer C, Johnson R. The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling. Biomed Pharmacother. 2020;131:110785.PubMedCrossRef
56.
Martinez-Una M, Lopez-Mancheno Y, Dieguez C, Fernandez-Rojo MA, Novelle MG. Unraveling the role of leptin in liver function and its relationship with Liver diseases. Int J Mol Sci 2020, 21(24).
57.
Vilarino-Garcia T, Polonio-Gonzalez ML, Perez-Perez A, Ribalta J, Arrieta F, Aguilar M, Obaya JC, Gimeno-Orna JA, Iglesias P, Navarro J et al. Role of leptin in obesity, Cardiovascular Disease, and type 2 diabetes. Int J Mol Sci 2024, 25(4).
58.
Kirichenko TV, Markina YV, Bogatyreva AI, Tolstik TV, Varaeva YR, Starodubova AV. The role of Adipokines in inflammatory mechanisms of obesity. Int J Mol Sci 2022, 23(23).
59.
60.
Kozawa J, Shimomura I. Ectopic fat accumulation in pancreas and heart. J Clin Med 2021, 10(6).
61.
Sakurai Y, Kubota N, Yamauchi T, Kadowaki T. Role of insulin resistance in MAFLD. Int J Mol Sci 2021, 22(8).
62.
Berardo C, Di Pasqua LG, Cagna M, Richelmi P, Vairetti M, Ferrigno A. Nonalcoholic fatty liver disease and non-alcoholic steatohepatitis: current issues and future perspectives in preclinical and clinical research. Int J Mol Sci 2020, 21(24).
63.
D’Oria R, Genchi VA, Caccioppoli C, Calderoni I, Marrano N, Biondi G, Borrelli A, Di Gioia L, Giorgino F, Laviola L. Impact of dysfunctional adipose tissue depots on the cardiovascular system. Int J Mol Sci 2022, 23(22).
64.
Kenchaiah S, Ding J, Carr JJ, Allison MA, Budoff MJ, Tracy RP, Burke GL, McClelland RL, Arai AE, Bluemke DA. Pericardial Fat and the risk of heart failure. J Am Coll Cardiol. 2021;77(21):2638–52.PubMedPubMedCentralCrossRef
65.
Zhu J, Yang Z, Li X, Chen X, Pi J, Zhuang T, Liu J, Li G, Peng S, Zhang L, et al. Association of periaortic fat and abdominal visceral fat with coronary artery atherosclerosis in Chinese middle aged and elderly patients undergoing computed tomography coronary angiography. Glob Heart. 2021;16(1):74.PubMedPubMedCentralCrossRef
66.
Cherubini A, Casirati E, Tomasi M, Valenti L. PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date. Expert Opin Ther Targets. 2021;25(12):1033–43.PubMedCrossRef
67.
Shen JH, Li YL, Li D, Wang NN, Jing L, Huang YH. The rs738409 (I148M) variant of the PNPLA3 gene and cirrhosis: a meta-analysis. J Lipid Res. 2015;56(1):167–75.PubMedPubMedCentralCrossRef
68.
Luukkonen PK, Qadri S, Lehtimaki TE, Juuti A, Sammalkorpi H, Penttila AK, Hakkarainen A, Orho-Melander M, Arola J, Yki-Jarvinen H. The PNPLA3-I148M variant confers an antiatherogenic lipid profile in insulin-resistant patients. J Clin Endocrinol Metab. 2021;106(1):e300–15.PubMedCrossRef
69.
Huang G, Wallace DF, Powell EE, Rahman T, Clark PJ, Subramaniam VN. Gene variants implicated in steatotic liver disease: opportunities for diagnostics and therapeutics. Biomedicines 2023, 11(10).
70.
Dongiovanni P, Petta S, Maglio C, Fracanzani AL, Pipitone R, Mozzi E, Motta BM, Kaminska D, Rametta R, Grimaudo S, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology. 2015;61(2):506–14.PubMedCrossRef
71.
Jonas W, Schurmann A. Genetic and epigenetic factors determining NAFLD risk. Mol Metab. 2021;50:101111.PubMedCrossRef
72.
Song Q, Zhang X. The role of gut-liver axis in gut microbiome dysbiosis associated NAFLD and NAFLD-HCC. Biomedicines 2022, 10(3).
73.
Han H, Jiang Y, Wang M, Melaku M, Liu L, Zhao Y, Everaert N, Yi B, Zhang H. Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis. Crit Rev Food Sci Nutr. 2023;63(12):1689–706.PubMedCrossRef
74.
Zhen J, Zhou Z, He M, Han HX, Lv EH, Wen PB, Liu X, Wang YT, Cai XC, Tian JQ, et al. The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases. Front Endocrinol (Lausanne). 2023;14:1085041.PubMedCrossRef
75.
Querio G, Antoniotti S, Geddo F, Levi R, Gallo MP. Modulation of endothelial function by TMAO, a gut microbiota-derived metabolite. Int J Mol Sci. 2023;24(6).
76.
Nesci A, Carnuccio C, Ruggieri V, D’Alessandro A, Di Giorgio A, Santoro L, Gasbarrini A, Santoliquido A, Ponziani FR. Gut microbiota and cardiovascular disease: evidence on the metabolic and inflammatory background of a complex relationship. Int J Mol Sci 2023, 24(10).
77.
78.
Wei J, Zhang Y, Dalbeth N, Terkeltaub R, Yang T, Wang Y, Yang Z, Li J, Wu Z, Zeng C, et al. Association between gut microbiota and elevated serum urate in two independent cohorts. Arthritis Rheumatol. 2022;74(4):682–91.PubMedCrossRef
79.
Zhao D, Cui H, Shao Z, Cao L. Abdominal obesity, chronic inflammation and the risk of non-alcoholic fatty liver disease. Ann Hepatol. 2023;28(4):100726.PubMedCrossRef
80.
Gutierrez-Cuevas J, Santos A, Armendariz-Borunda J. Pathophysiological molecular mechanisms of obesity: a link between MAFLD and NASH with cardiovascular diseases. Int J Mol Sci 2021, 22(21).
81.
Dao AD, Nguyen VH, Ito T, Cheung R, Nguyen MH. Prevalence, characteristics, and mortality outcomes of obese and nonobese MAFLD in the United States. Hepatol Int. 2023;17(1):225–36.PubMedCrossRef
82.
Pipitone RM, Ciccioli C, Infantino G, La Mantia C, Parisi S, Tulone A, Pennisi G, Grimaudo S, Petta S. MAFLD: a multisystem disease. Ther Adv Endocrinol Metab. 2023;14:20420188221145549.PubMedPubMedCentralCrossRef
83.
Finney AC, Das S, Kumar D, McKinney MP, Cai B, Yurdagul A Jr., Rom O. The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease. Front Cardiovasc Med. 2023;10:1116861.PubMedPubMedCentralCrossRef
84.
McCullough A, Previs SF, Dasarathy J, Lee K, Osme A, Kim C, Ilchenko S, Lorkowski SW, Smith JD, Dasarathy S, et al. HDL flux is higher in patients with nonalcoholic fatty liver disease. Am J Physiol Endocrinol Metab. 2019;317(5):E852–62.PubMedPubMedCentralCrossRef
85.
Golubeva JA, Sheptulina AF, Elkina AY, Liusina EO, Kiselev AR, Drapkina OM. Which comes first, nonalcoholic fatty liver disease or arterial hypertension? Biomedicines 2023, 11(9).
86.
Sata Y, Head GA, Denton K, May CN, Schlaich MP. Role of the sympathetic nervous system and its modulation in renal hypertension. Front Med. 2018;5:82.CrossRef
87.
Zhao YC, Zhao GJ, Chen Z, She ZG, Cai J, Li H. Nonalcoholic fatty liver disease: an emerging driver of hypertension. Hypertension. 2020;75(2):275–84.PubMedCrossRef
88.
Yiannikouris F, Gupte M, Putnam K, Thatcher S, Charnigo R, Rateri DL, Daugherty A, Cassis LA. Adipocyte deficiency of angiotensinogen prevents obesity-induced hypertension in male mice. Hypertension. 2012;60(6):1524–30.PubMedCrossRef
89.
Musso G, Saba F, Cassader M, Paschetta E, De Michieli F, Pinach S, Framarin L, Berrutti M, Leone N, Parente R, et al. Angiotensin II type 1 receptor rs5186 gene variant predicts Incident NAFLD and Associated hypertension: role of dietary fat-induced pro-inflammatory cell activation. Am J Gastroenterol. 2019;114(4):607–19.PubMedCrossRef
90.
Cho IJ, Oh DH, Yoo J, Hwang YC, Ahn KJ, Chung HY, Jeong SW, Moon JY, Lee SH, Lim SJ, et al. Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway. Sci Rep. 2021;11(1):9894.PubMedPubMedCentralCrossRef
91.
Zhou XD, Cai J, Targher G, Byrne CD, Shapiro MD, Sung KC, Somers VK, Chahal CAA, George J, Chen LL, et al. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovasc Diabetol. 2022;21(1):270.PubMedPubMedCentralCrossRef
92.
Koutentakis M, Kucinski J, Swieczkowski D, Surma S, Filipiak KJ, Gasecka A. The ketogenic effect of SGLT-2 inhibitors-beneficial or harmful? J Cardiovasc Dev Dis 2023, 10(11).
93.
Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut. 2010;59(10):1410–5.PubMedCrossRef
94.
Koehler EM, Plompen EP, Schouten JN, Hansen BE, Darwish Murad S, Taimr P, Leebeek FW, Hofman A, Stricker BH, Castera L, et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study. Hepatology. 2016;63(1):138–47.PubMedCrossRef
95.
Koulaouzidis G, Charisopoulou D, Kukla M, Marlicz W, Rydzewska G, Koulaouzidis A, Skonieczna-Zydecka K. Association of non-alcoholic fatty liver disease with coronary artery calcification progression: a systematic review and meta-analysis. Prz Gastroenterol. 2021;16(3):196–206.PubMedPubMedCentral
96.
Sung KC, Yoo TK, Lee MY, Byrne CD, Zheng MH, Targher G. Comparative associations of nonalcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease with coronary artery calcification: a cross-sectional and longitudinal cohort study. Arterioscler Thromb Vasc Biol. 2023;43(3):482–91.PubMedCrossRef
97.
Chen S, Xue H, Huang R, Chen K, Zhang H, Chen X. Associations of MAFLD and MAFLD subtypes with the risk of the incident myocardial infarction and stroke. Diabetes Metab. 2023;49(5):101468.PubMedCrossRef
98.
Peng D, Yu Z, Wang M, Shi J, Sun L, Zhang Y, Zhao W, Chen C, Tang J, Wang C, et al. Association of metabolic dysfunction-associated fatty liver disease with left ventricular diastolic function and cardiac morphology. Front Endocrinol. 2022;13:935390.CrossRef
99.
Wei Z, Huang Z, Song Z, Zhao W, Zhao D, Tan Y, Chen S, Yang P, Li Y, Wu S. Metabolic dysfunction-associated fatty liver disease and incident heart failure risk: the Kailuan cohort study. Diabetol Metab Syndr. 2023;15(1):137.PubMedPubMedCentralCrossRef
100.
Wu S, Li Y, Zhang Y, Su X, Zuo Y, Chen G, Xu G, Chen S, He Y, Wang A. Sex and age differences in the Association between Metabolic Dysfunction-Associated fatty liver disease and heart failure: a prospective cohort study. Circ Heart Fail. 2024;17(2):e010841.PubMedCrossRef
101.
Lei F, Qin JJ, Song X, Liu YM, Chen MM, Sun T, Huang X, Deng KQ, Zuo X, Yao D, et al. The prevalence of MAFLD and its association with atrial fibrillation in a nationwide health check-up population in China. Front Endocrinol (Lausanne). 2022;13:1007171.PubMedCrossRef
102.
Keskin M, Hayiroglu MI, Uzun AO, Guvenc TS, Sahin S, Kozan O. Effect of nonalcoholic fatty liver disease on in-hospital and long-term outcomes in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2017;120(10):1720–6.PubMedCrossRef
103.
Xie W, Gan J, Zhou X, Tian H, Pan X, Liu W, Li X, Du J, Xu A, Zheng M, et al. Myocardial infarction accelerates the progression of MASH by triggering immunoinflammatory response and induction of periosti. Cell Metab. 2024;36(6):1269–e12861269.PubMedCrossRef
104.
Mantovani A, Dauriz M, Sandri D, Bonapace S, Zoppini G, Tilg H, Byrne CD, Targher G. Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: an updated meta-analysis. Liver Int. 2019;39(4):758–69.PubMedCrossRef
105.
van Kleef LA, Lu Z, Ikram MA, de Groot NMS, Kavousi M, de Knegt RJ. Liver stiffness not fatty liver disease is associated with atrial fibrillation: the Rotterdam study. J Hepatol. 2022;77(4):931–8.PubMedCrossRef
106.
Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48(5):835–47.PubMedCrossRef
107.
Myers RP, Elkashab M, Ma M, Crotty P, Pomier-Layrargues G. Transient elastography for the noninvasive assessment of liver fibrosis: a multicentre Canadian study. Can J Gastroenterol. 2010;24(11):661–70.PubMedPubMedCentral
108.
Liver, EAftSot. Hígado ALpeEd: EASL-ALEH clinical practice guidelines: non-invasive tests for evalution of liver disease severity and prognosis. J Hepatol. 2015;63:237–64.CrossRef
109.
Boeckmans J, Sandrin L, Knackstedt C, Schattenberg JM. Liver stiffness as a cornerstone in heart disease risk assessment. Liver Int. 2024;44(2):344–56.PubMedCrossRef
110.
111.
Alem SA, Abdellatif Z, Mabrouk M, Zayed N, Elsharkawy A, Khairy M, Musa S, Anwar I, Yosry A. Diagnostic accuracy of acoustic radiation force impulse elastography (ARFI) in comparison to other non-invasive modalities in staging of liver fibrosis in chronic HCV patients: single-center experience. Abdom Radiol (NY). 2019;44(8):2751–8.PubMedCrossRef
112.
Vidili G, Arru M, Meloni P, Solinas G, Atzori S, Maida I. Comparison of 2D Shear Wave Elastography and transient elastography in non-invasive evaluation of liver fibrosis in Hepatitis C Virus-Related Chronic Liver Disease. J Clin Med 2024, 13(14).
113.
Erre GL, Cadoni ML, Meloni P, Castagna F, Mangoni AA, Piga M, Passiu G, Carru C, Zinellu A, Vidili G. Methotrexate therapy is not associated with increased liver stiffness and significant liver fibrosis in rheumatoid arthritis patients: a cross-sectional controlled study with real-time two-dimensional shear wave elastography. Eur J Intern Med. 2019;69:57–63.PubMedCrossRef
114.
Erre GL, Castagna F, Sauchella A, Meloni P, Mangoni AA, Farina G, Woodman R, Dore MP, Vidili G. Prevalence and risk factors of moderate to severe hepatic steatosis in patients with rheumatoid arthritis: an ultrasonography cross-sectional case-control study. Ther Adv Musculoskelet Dis. 2021;13:1759720X211042739.PubMedPubMedCentralCrossRef
115.
Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice. J Hepatol. 2016;65(5):1006–16.PubMedPubMedCentralCrossRef
116.
Thomas Elgeti MB, Hamm B. Ju¨rgen Braun, and Ingolf Sack: <2010 Cardiac magnetic resonance Elastography toward the diagnosis of abnormal myocardial Relaxation.pdf>. Invest Radiol. 2010;45(12):782–7.PubMed
117.
Park CC, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, Hooker J, Sy E, Savides MT, Alquiraish MH, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology. 2017;152(3):598–e607592.PubMedCrossRef
118.
AlShaalan R, Aljiffry M, Al-Busafi S, Metrakos P, Hassanain M. Nonalcoholic fatty liver disease: noninvasive methods of diagnosing hepatic steatosis. Saudi J Gastroenterol. 2015;21(2):64–70.PubMedPubMedCentralCrossRef
119.
van Ewijk PA, Schrauwen-Hinderling VB, Bekkers SC, Glatz JF, Wildberger JE, Kooi ME. MRS: a noninvasive window into cardiac metabolism. NMR Biomed. 2015;28(7):747–66.PubMedCrossRef
120.
Iqra Nadeem Kazi M, Lily Kuo M, Eugenia Tsai M. Noninvasive methods for assessing liver fibrosis and Steatosis. Gastroenterol Hepatol 2024, 20(1).
121.
Ciardullo S, Cannistraci R, Muraca E, Zerbini F, Perseghin G. Liver fibrosis, NT-ProBNP and mortality in patients with MASLD: a population-based cohort study. Nutr Metab Cardiovasc Dis. 2024;34(4):963–71.PubMedCrossRef
122.
Vieira Barbosa J, Milligan S, Frick A, Broestl J, Younossi Z, Afdhal N, Lai M. Fibrosis-4 Index can independently predict major adverse Cardiovascular events in nonalcoholic fatty liver disease. Am J Gastroenterol. 2022;117(3):453–61.PubMedCrossRef
123.
Durak H, Çetin M, Emlek N, Ergül E, Özyıldız AG, Öztürk M, Duman H, Yılmaz AS, Şatıroğlu Ö. FIB-4 liver fibrosis index correlates with aortic valve sclerosis in non-alcoholic population. 2024, 41(1):e15732.
124.
Shibata N, Ito T, Toyoda H, Tanaka A, Morita Y, Kanzaki Y, Watanabe N, Yoshioka N, Morishima I. Predictability of noninvasive liver fibrosis score for cardiac events in patients with nonalcoholic fatty liver disease. Eur Heart J 2023, 44(Supplement_2).
125.
Lee J, Vali Y, Boursier J, Spijker R, Anstee QM, Bossuyt PM, Zafarmand MH. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review. Liver Int. 2021;41(2):261–70.PubMedPubMedCentralCrossRef
126.
Ballestri S, Mantovani A, Baldelli E, Lugari S, Maurantonio M, Nascimbeni F, Marrazzo A, Romagnoli D, Targher G, Lonardo A. Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease. Diagnostics (Basel) 2021, 11(1).
127.
van der Bijl P, Kuneman JH, Bax JJ. Pericoronary adipose tissue attenuation: diagnostic and prognostic implications. Eur Heart J Cardiovasc Imaging. 2022;23(12):e537–8.PubMedCrossRef
128.
Yuvaraj J, Lin A, Nerlekar N, Munnur RK, Cameron JD, Dey D, Nicholls SJ, Wong DTL. Pericoronary Adipose tissue attenuation is Associated with High-Risk Plaque and subsequent Acute Coronary Syndrome in patients with stable coronary artery disease. Cells 2021, 10(5).
129.
Takahata Y, Takahashi A, Anzai Y, Abe N, Sugaya T, Fujita M, Hayashi M, Abe K, Ohira H. Lifestyle factors affecting new-onset nonalcoholic fatty liver disease. Prev Med Rep. 2024;37:102577.PubMedCrossRef
130.
Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, Fava JL, Wing RR. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51(1):121–9.PubMedCrossRef
131.
Niederseer D, Wernly B, Aigner E, Stickel F, Datz C. NAFLD and cardiovascular diseases: epidemiological, mechanistic and therapeutic considerations. J Clin Med. 2021;10(3).
132.
Akhavan Rezayat A, Dadgar Moghadam M, Ghasemi Nour M, Shirazinia M, Ghodsi H, Rouhbakhsh Zahmatkesh MR, Tavakolizadeh Noghabi M, Hoseini B, Akhavan Rezayat K. Association between smoking and non-alcoholic fatty liver disease: a systematic review and meta-analysis. SAGE Open Med. 2018;6:2050312117745223.PubMedPubMedCentralCrossRef
133.
Laursen TL, Hagemann CA, Wei C, Kazankov K, Thomsen KL, Knop FK, Gronbaek H. Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects. World J Hepatol. 2019;11(2):138–49.PubMedPubMedCentralCrossRef
134.
Stefan N, Haring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019;7(4):313–24.PubMedCrossRef
135.
Quinn CE, Hamilton PK, Lockhart CJ, McVeigh GE. Thiazolidinediones: effects on insulin resistance and the cardiovascular system. Br J Pharmacol. 2008;153(4):636–45.PubMedCrossRef
136.
Guru B, Tamrakar AK, Manjula SN, Prashantha Kumar BR. Novel dual PPARalpha/gamma agonists protect against liver steatosis and improve insulin sensitivity while avoiding side effects. Eur J Pharmacol. 2022;935:175322.PubMedCrossRef
137.
Mao T, Zhang C, Yang S, Bi Y, Li M, Yu J. Semaglutide alters gut microbiota and improves NAFLD in db/db mice. Biochem Biophys Res Commun. 2024;710:149882.PubMedCrossRef
138.
Cheung KS, Ng HY, Hui RWH, Lam LK, Mak LY, Ho YC, Tan JT, Chan EW, Seto WK, Yuen MF et al. Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Hepatology 2024.
139.
Sumida Y, Naito Y, Tanaka S, Sakai K, Inada Y, Taketani H, Kanemasa K, Yasui K, Itoh Y, Okanoue T, et al. Long-term (> = 2 year) efficacy of vitamin E for non-alcoholic steatohepatitis. Hepatogastroenterology. 2013;60(126):1445–50.PubMed
140.
Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956–65.PubMedCrossRef
141.
Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, Yoneda M, Behling C, Cummings OW, Tang Y, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299–310.PubMedCrossRef
142.
Petta S, Targher G, Romeo S, Pajvani UB, Zheng MH, Aghemo A, Valenti LVC. The first MASH drug therapy on the horizon: current perspectives of resmetirom. Liver Int 2024.
143.
Loomba R, Sanyal AJ, Kowdley KV, Bhatt DL, Alkhouri N, Frias JP, Bedossa P, Harrison SA, Lazas D, Barish R, et al. Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH. N Engl J Med. 2023;389(11):998–1008.PubMedPubMedCentralCrossRef
144.
Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, Anstee QM, Hussain SA, Newsome PN, Ratziu V, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391(4):311–9.PubMedCrossRef
145.
Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–77.PubMedCrossRef
146.
Simon TG, Henson J, Osganian S, Masia R, Chan AT, Chung RT, Corey KE. Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019;17(13):2776-e27842774.PubMedPubMedCentralCrossRef
147.
Ballestri S, Capitelli M, Fontana MC, Arioli D, Romagnoli E, Graziosi C, Lonardo A, Marietta M, Dentali F, Cioni G. Direct oral anticoagulants in patients with liver disease in the era of non-alcoholic fatty liver disease global epidemic: a narrative review. Adv Ther. 2020;37(5):1910–32.PubMedPubMedCentralCrossRef
148.
Pastori D, Polimeni L, Baratta F, Pani A, Del Ben M, Angelico F. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis. 2015;47(1):4–11.PubMedCrossRef
149.
Pastori D, Pani A, Di Rocco A, Menichelli D, Gazzaniga G, Farcomeni A, D’Erasmo L, Angelico F, Del Ben M, Baratta F. Statin liver safety in non-alcoholic fatty liver disease: a systematic review and metanalysis. Br J Clin Pharmacol. 2022;88(2):441–51.PubMedCrossRef
150.
Ryoo JH, Suh YJ, Shin HC, Cho YK, Choi JM, Park SK. Clinical association between non-alcoholic fatty liver disease and the development of hypertension. J Gastroenterol Hepatol. 2014;29(11):1926–31.PubMedCrossRef
151.
Aneni EC, Oni ET, Martin SS, Blaha MJ, Agatston AS, Feldman T, Veledar E, Conceicao RD, Carvalho JA, Santos RD, et al. Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk. J Hypertens. 2015;33(6):1207–14.PubMedCrossRef
152.
Li Y, Xu H, Wu W, Ye J, Fang D, Shi D, Li L. Clinical application of angiotensin receptor blockers in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Oncotarget. 2018;9(35):24155–67.PubMedPubMedCentralCrossRef
Metadata
Title
Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review
Authors
Haixiang Zheng
Leonardo Antonio Sechi
Eliano Pio Navarese
Gavino Casu
Gianpaolo Vidili
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2024
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-024-02434-5

Other articles of this Issue 1/2024

Cardiovascular Diabetology 1/2024 Go to the issue

Research

Acute-to-chronic glycemic ratio as an outcome predictor in ischemic stroke in patients with and without diabetes mellitus

Research

Mean platelet volume (MPV) as new marker of diabetic macrovascular complications in patients with different glucose homeostasis

Research

Impaired GK-GKRP interaction rather than direct GK activation worsens lipid profiles and contributes to long-term complications: a Mendelian randomization study

Research

Additive effect of metabolic dysfunction-associated fatty liver disease on left ventricular function and global strain in type 2 diabetes mellitus patients: a 3.0 T cardiac magnetic resonance feature tracking study

Research

Predicting gestational diabetes mellitus risk at 11–13 weeks’ gestation: the role of extrachromosomal circular DNA

Research

Association of RASGRP1 polymorphism with vascular complications in Chinese diabetic patients with glycemic control and antihypertensive treatment

2024 ESC Congress

Noise pollution dangerous for heart health

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Read more

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

Keynote webinar | Spotlight on medication adherence

  • Webinar | 27-06-2024 | 18:00 (CEST)

Medication non-adherence is a major barrier to effective healthcare delivery; half of all patients do not follow their doctor’s recommendations or treatment plan.

Our experts explain the fundamentals with a practical discussion of how to manage non-adherence in two common scenarios: hypertension and asthma control.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Watch now
Image Credits